PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) GENOTYPI

A genetic test to assess mutations in the PAI-1 gene, which can affect blood clotting and fibrinolysis. Elevated levels of PAI-1 are associated with thrombotic disorders and cardiovascular disease risk. The test is useful for assessing inherited clotting disorders and guiding anticoagulant therapy.

Also known asPlasminogen Activator Inhibitor-1 (pai-1) Genotyping Plasminogen Activator Inhibitor-1 (pai-1) Genotyping

Available via

Home Collection, Lab Visit

Contains

2 parameters

Earliest reports in

7 Working Days

Test details

PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) GENOTYPI Test in Bengaluru Overview

Preparations

No special preparations needed

Test included
PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) GENOTYPI includes 2 parameters

  • Plasminogen Activator Inhibitor-1 (pai-1) Genotyping
  • Clinical Details
Frequently Asked Questions

The PAI-1 test measures the level of plasminogen activator inhibitor-1 in the blood. PAI-1 is a protein that regulates blood clot formation by inhibiting tissue plasminogen activator (tPA). Abnormal PAI-1 levels are associated with an increased risk of thrombosis and cardiovascular disease.

The test is recommended for individuals with a personal or family history of thrombosis, recurrent miscarriages, or unexplained cardiovascular events. It is also used to assess clotting disorders and monitor patients undergoing fibrinolytic therapy.

A blood sample is collected, and PAI-1 levels are measured using immunoassay techniques. The results help determine whether abnormal levels of PAI-1 are contributing to an increased risk of clot formation or impaired fibrinolysis.

Elevated PAI-1 levels indicate a higher risk of clot formation, potentially leading to thrombotic events such as deep vein thrombosis (DVT) and myocardial infarction. Low PAI-1 levels may increase the risk of excessive bleeding due to impaired clot formation.

Management strategies may include anticoagulant therapy, lifestyle modifications, and addressing underlying conditions that may contribute to abnormal PAI-1 levels. Regular monitoring is essential for individuals at high risk of thrombotic events.

Test code

RD1432

Specimen vol. and vacutainer information
SpecimenVacutainerVolume
Edta Whole BloodLavender Vacutainer4 ML

Specimen stability information

Edta Whole Blood

Specimen rejection criteria

Test run frequency

Monday,Tuesday,Wednesday,Thursday,Friday,Saturday,Sunday TIME - 09:30

Turn around time

7 Working Days

Performing locations

Department

  • Advanced Molecular Diagnostics R&d

CPT and Loinc codes

PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) GENOTYPI

12500